#Sweden #Stockholm #Annual Report #Nevisense #SciBase

SciBase Releases Annual Report 2024

On May 23, 2025, SciBase announced the availability of its Annual Report for 2024, a key document reflecting the company's activities, achievements, and financial performance in the dermatology sector. The report can be accessed digitally on the company's website at www.scibase.com. This strategic move underscores SciBase's commitment to transparency and engagement with its stakeholders.

Key Highlights of the Annual Report

The report provides a detailed overview of SciBase's operational metrics, focusing on its innovative product, Nevisense, which merges Artificial Intelligence (AI) with advanced Electrical Impedance Spectroscopy (EIS) technology. This unique platform is designed for early detection and prevention of skin conditions, empowering healthcare providers with the tools necessary for effective diagnosis and treatment. SciBase's overarching goal is to minimize patient suffering and enhance healthcare outcomes through timely intervention, ultimately reducing healthcare costs.

A Look at Nevisense

Nevisense represents a significant leap in dermatology technology, built on over two decades of research from the esteemed Karolinska Institute in Stockholm, Sweden. The platform's cutting-edge capabilities enable clinicians to achieve higher diagnostic accuracy, allowing for better patient management and proactive health measures. As a product of rigorous scientific inquiry and innovation, Nevisense is not just a tool but part of SciBase's mission to save lives through improved healthcare delivery.

Distribution of the Report

In addition to the online version, a printed edition of the Annual Report will be made available upon request from shareholders, reflecting SciBase's ongoing commitment to maintaining robust communication lines with its investors. Interested stakeholders can also reach out directly to SciBase for specific inquiries related to the report or business operations.
For further details, shareholders are encouraged to contact Michael Colérus, CFO, at +46 70 341 34 72 or via email at [email protected].

SciBase in the Financial Market

Since its listing on the Nasdaq First North Growth Market on June 2, 2015, SciBase has seen steady growth and increased visibility in the competitive field of medical technology. Carnegie Investment Bank AB serves as the company's Certified Advisor, supporting its market activities and ensuring compliance with regulatory standards. The 2024 Annual Report will reflect not only past achievements but also the company's strategic outlook, painting a picture of forthcoming projects and expansions in the global market.

Looking Forward

As SciBase continues to innovate and expand its offerings, the Annual Report serves as a foundational document that will guide future investments and strategies. The company's leadership remains focused on enhancing product offerings and furthering its research initiatives to solidify its position as a leader in dermatological advancements.

In conclusion, the publication of the Annual Report marks an important moment in SciBase's journey, highlighting its successes while also laying the groundwork for future endeavors in improving skin health management. The comprehensive document is a testament to the company's resolve in pioneering advancements in medical technology for better patient outcomes.